The Treatment of Lenalidomide in Patients With POEMS Syndrome
Status:
Unknown status
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Lenalidomide is a immunomodulatory drug derived from thalidomide, without neurotoxicity.
Lenalidomide blocks the increased secretion of interleukin-6, tumor necrosis factor alpha and
vascular endothelial growth factor (VEGF). The association with dexamethasone increased
Lenalidomide response rate.
More recently the efficacy of Lenalidomide has been reported in a patient with POEMS
(POEMS:polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes)
syndrome with improvement of clinical condition and reduction of vascular endothelial growth
factor (VEGF) and interleukin-6 (IL-6) level.